Fish oil, aspirin and heart
Several studies on the effect of aspirin and fish oil on the development of cardiovascular diseases were published this week.
In the work of Professor Gaziano, cardiologist-prevention of Brigham and Women's Hospital, it is noted that aspirin has low effectiveness in preventing heart attacks in people at risk (smoking, high blood pressure, high cholesterol). Among more than 12,500 patients, heart problems were observed in 269 (4.3%) of the aspirin group and in 281 (4.5%) of the placebo group.
Dr. Bowman and her colleagues published the results of a large-scale work in which they studied the effect of fatty acids contained in fish oil and aspirin on the development of cardiovascular diseases in patients with type 2 diabetes. The study involved 15,480 people who took various combinations of fish oil, aspirin and placebo for 7 years. The data obtained indicate the benefits of aspirin and the lack of effectiveness of fish oil for the prevention of diseases of the cardiovascular system in diabetics. At the same time, taking aspirin has been shown to increase the risk of internal bleeding.
The data on the lack of effectiveness of fish oil obtained during this study correspond to those obtained earlier. Based on this, it can be concluded that the appointment of fish oil for the prevention of heart problems does not make sense.
Type 2 diabetes now has the scale of an epidemic and is associated with a serious risk of cardiovascular diseases. Aspirin could be an excellent preventive remedy due to its low cost and high availability. However, due to the ambiguous results of studies, the question of whether it is worth recommending the use of aspirin for the prevention of cardiovascular diseases remains open.
Article by Bowman et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes published in American Heart Journal.
Article by Gaziano et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomized, double-blind, placebo-controlled trial published in The Lancet.
Anastasia Poznyak, portal "Eternal Youth" http://vechnayamolodost.ru /